Diabetes mellitus, the single most important cause of vascular disease in the industrialized world, is also associated with bone loss and impaired fracture healing. Mesenchymal stem cells (MSCs) have the potential to differentiate into osteoblasts, chondrocytes and adipocytes and other mesenchymal cells and play a central role in bone formation and repair. Because of this, we have investigated the possibility that diabetes has direct effects on MSCs in vivo and that this might represent a cellular basis for diabetes-induced osteoporosis. We isolated MSCs from rats with streptozotocin-induced diabetes and analysed them ex vivo for their ability to proliferate and differentiate in the fibroblastic colony-forming unit assay. Effects of diabetes on bone metabolism in vivo were determined by analysing tibiae from control and diabetic animals by quantitative computerized tomography. The total number of colonies and osteoblastic colonies staining positive for alkaline phosphatase were quantified and both colony size and number were found to be significantly reduced in diabetic rats. The changes appear to be mediated by the induction of apoptosis and senescence by advanced glycation end products (AGEs), together with an increase in the receptor for AGEs (RAGE). These changes were paralleled by extensive loss of trabecular bone in the tibiae of the diabetic animals. These data suggest that MSCs become exhausted during diabetes and lose their differentiation potential, leading to a net loss of trabecular bone. Therefore, direct effects on MSCs may be responsible for some of the orthopaedic effects associated with diabetes.

Keywords:
Bone biology, Cell biology, Diabetic animals, Free radicals, Mesenchymal stem cells
1.
Abedin, M., Y. Tintut, L.L. Demer (2004) Mesenchymal stem cells and the artery wall. Circ Res 95: 671–676.
2.
Bergman, R.J., D. Gazit, A.J. Kahn, H. Gruber, S. McDougall, T.J. Hahn (1996) Age-related changes in osteogenic stem cells in mice. J Bone Miner Res 11: 568–577.
3.
Bland, R. (2000) Steroid hormone receptor expression and action in bone. Clin Sci (Lond) 98: 217–240.
4.
Bohlender, J.M., S. Franke, G. Stein, G. Wolf (2005) Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 289: F645–F659.
5.
Chen, J., S.V. Brodsky, D.M. Goligorsky, D.J. Hampel, H. Li, S.S. Gross, M.S. Goligorsky (2002) Glycated collagen I induces premature senescence-like phenotypic changes in endothelial cells. Circ Res 90: 1290–1298.
6.
Chiu, K.C., A. Chu, V.L. Go, M.F. Saad (2004) Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 79: 820–825.
7.
Cortizo, A.M., M.G. Lettieri, D.A. Barrio, N. Mercer, S.B. Etcheverry, A.D. McCarthy (2003) Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK). Mol Cell Biochem 250: 1–10.
8.
Dennis, J.E., A.I. Caplan (1996) Analysis of the developmental potential of conditionally immortal marrow-derived mesenchymal progenitor cells isolated from the H-2Kb-tsA58 transgenic mouse. Connect Tissue Res 35: 93–99.
9.
Ding, K.H., Z.Z. Wang, M.W. Hamrick, Z.B. Deng, L. Zhou, B. Kang, S.L. Yan, J.X. She, D.M. Stern, C.M. Isales, Q.S. Mi (2006) Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes-related bone loss. Biochem Biophys Res Commun 340: 1091–1097.
10.
Dobson, K.R., L. Reading, M. Haberey, X. Marine, A. Scutt (1999) Centrifugal isolation of bone marrow from bone: an improved method for the recovery and quantitation of bone marrow osteoprogenitor cells from rat tibiae and femorae. Calcif Tissue Int 65: 411–413.
11.
Federici, M., R. Lauro (2005) Review article: diabetes and atherosclerosis – running on a common road. Aliment Pharmacol Ther 22(suppl 2): 11–15.
12.
Franke, S., H. Siggelkow, G. Wolf, G. Hein (2007) Advanced glycation endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch Physiol Biochem 113: 154–161.
13.
Gallacher, S.J., J.A. Fenner, B.M. Fisher, J.D. Quin, W.D. Fraser, F.C. Logue, R.A. Cowan, I.T. Boyle, A.C. MacCuish (1993) An evaluation of bone density and turnover in premenopausal women with type 1 diabetes mellitus. Diabet Med 10: 129–133.
14.
Sanguineti, R., D. Storace, F. Monacelli, A. Federici, P. Odetti (2008) Pentosidine effects on human osteoblasts in vitro. Ann N Y Acad Sci 1126: 166–172.
15.
Herskind, A.M., K. Christensen, K. Norgaard-Andersen, J.F. Andersen (1992) Diabetes mellitus and healing of closed fractures. Diabetes Metab 18: 63–64.
16.
Isaia, G., L. Bodrato, V. Carlevatto, M. Mussetta, G. Salamano, G.M. Molinatti (1987) Osteoporosis in type II diabetes. Acta Diabetol Lat 24: 305–310.
17.
Jakus, V., K. Bauerova, D. Michalkova, J. Carsky (2001) Serum levels of advanced glycation end products in poorly metabolically controlled children with diabetes mellitus: relation to HbA1c. Diabetes Nutr Metab 14: 207–211.
18.
Katayama, Y., T. Akatsu, M. Yamamoto, N. Kugai, N. Nagata (1996) Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res 11: 931–937.
19.
Kayath, M.J., E.F. Tavares, S.A. Dib, J.G. Vieira (1998) Prospective bone mineral density evaluation in patients with insulin-dependent diabetes mellitus. J Diabetes Complications 12: 133–139.
20.
Kent, S. (1976) Is diabetes a form of accelerated aging? Geriatrics 31: 140, 145, 149–151.
21.
Kume, S., S. Kato, S. Yamagishi, Y. Inagaki, S. Ueda, N. Arima, T. Okawa, M. Kojiro, K. Nagata (2005) Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 20: 1647–1658.
22.
Kuznetsov, S.A., A.J. Friedenstein, P.G. Robey (1997) Factors required for bone marrow stromal fibroblast colony formation in vitro. Br J Haematol 97: 561–570.
23.
Lander, H.M., J.M. Tauras, J.S. Ogiste, O. Hori, R.A. Moss, A.M. Schmidt (1997) Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272: 17810–17814.
24.
Levin, M.E., V.C. Boisseau, L.V. Avioli (1976) Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N Engl J Med 294: 241–245.
25.
Loeser, R.F., R.R. Yammani, C.S. Carlson, H. Chen, A. Cole, H.J. Im, L.S. Bursch, S.D. Yan (2005) Articular chondrocytes express the receptor for advanced glycation end products: potential role in osteoarthritis. Arthritis Rheum 52: 2376–2385.
26.
Majeska, R.J., B.C. Nair, G.A. Rodan (1985) Glucocorticoid regulation of alkaline phosphatase in the osteoblastic osteosarcoma cell line ROS 17/2.8. Endocrinology 116: 170–179.
27.
Makimura, H., T.M. Mizuno, F. Isoda, J. Beasley, J.H. Silverstein, C.V. Mobbs (2003) Role of glucocorticoids in mediating effects of fasting and diabetes on hypothalamic gene expression. BMC Physiol 3: 5.
28.
Mathiassen, B., S. Nielsen, J.S. Johansen, D. Hartwell, J. Ditzel, P. Rodbro, C. Christiansen (1990) Long-term bone loss in insulin-dependent diabetic patients with microvascular complications. J Diabet Complications 4: 145–149.
29.
McCarthy, A.D., A.M. Cortizo, G. Gimenez Segura, L. Bruzzone, S.B. Etcheverry (1998) Non-enzymatic glycosylation of alkaline phosphatase alters its biological properties. Mol Cell Biochem 181: 63–69.
30.
McCarthy, A.D., T. Uemura, S.B. Etcheverry, A.M. Cortizo (2004) Advanced glycation endproducts interfere with integrin-mediated osteoblastic attachment to a type-I collagen matrix. Int J Biochem Cell Biol 36: 840–848.
31.
McNair, P. (1988) Bone mineral metabolism in human type 1 (insulin dependent) diabetes mellitus. Dan Med Bull 35: 109–121.
32.
McNair, P., S. Madsbad, M.S. Christensen, C. Christiansen, O.K. Faber, C. Binder, I. Transbol (1979) Bone mineral loss in insulin-treated diabetes mellitus: studies on pathogenesis. Acta Endocrinol (Copenh) 90: 463–472.
33.
Mercer, N., H. Ahmed, A.D. McCarthy, S.B. Etcheverry, G.R. Vasta, A.M. Cortizo (2004) AGE-R3/galectin-3 expression in osteoblast-like cells: regulation by AGEs. Mol Cell Biochem 266: 17–24.
34.
Nakamura, T., K. Sakamoto (2001) Reactive oxygen species up-regulates cyclooxygenase-2, p53, and Bax mRNA expression in bovine luteal cells. Biochem Biophys Res Commun 284: 203–210.
35.
Nicodemus, K.K., A.R. Folsom (2001) Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24: 1192–1197.
36.
Noble, M., M. Mayer-Proschel, C. Proschel (2005) Redox regulation of precursor cell function: insights and paradoxes. Antioxid Redox Signal 7: 1456–1467.
37.
Ohgami, N., R. Nagai, M. Ikemoto, H. Arai, A. Kuniyasu, S. Horiuchi, H. Nakayama (2001) Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products. J Biol Chem 276: 3195–3202.
38.
Prockop, D.J. (1997) Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276: 71–74.
39.
Quarto, R., D. Thomas, C.T. Liang (1995) Bone progenitor cell deficits and the age-associated decline in bone repair capacity. Calcif Tissue Int 56: 123–129.
40.
Ranhotra, H.S., R. Sharma (2000) Streptozotocin-induced diabetes and glucocorticoid receptor regulation: tissue- and age-specific variation. Mech Ageing Dev 119: 15–24.
41.
Guo, Y., L. Einhorn, M. Kelley, K. Hirota, J. Yodoi, R. Reinbold, H. Scholer, H. Ramsey, R. Hromas (2004) Redox regulation of the embryonic stem cell transcription factor oct-4 by thioredoxin. Stem Cells 22: 259–264.
42.
Saretzki, G., L. Armstrong, A. Leake, M. Lako, T. von Zglinicki (2004) Stress defense in murine embryonic stem cells is superior to that of various differentiated murine cells. Stem Cells 22: 962–971.
43.
Saretzki, G., T. Walter, S. Atkinson, J.F. Passos, B. Bareth, W.N. Keith, R. Stewart, S. Hoare, M. Stojkovic, L. Armstrong, T. von Zglinicki, M. Lako (2008) Downregulation of multiple stress defense mechanisms during differentiation of human embryonic stem cells. Stem Cells 26: 455–464.
44.
Schwartz, A.V. (2003) Diabetes mellitus: does it affect bone? Calcif Tissue Int 73: 515–519.
45.
Schwartz, A.V., D.E. Sellmeyer, K.E. Ensrud, J.A. Cauley, H.K. Tabor, P.J. Schreiner, S.A. Jamal, D.M. Black, S.R. Cummings (2001) Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 86: 32–38.
46.
Scutt, A., P. Bertram (1995) Bone marrow cells are targets for the anabolic actions of prostaglandin E2 on bone: induction of a transition from nonadherent to adherent osteoblast precursors. J Bone Miner Res 10: 474–487.
47.
Sekiya, I., B.L. Larson, J.R. Smith, R. Pochampally, J.G. Cui, D.J. Prockop (2002) Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells 20: 530–541.
48.
Sethe, S., A. Scutt, A. Stolzing (2006) Aging of mesenchymal stem cells. Ageing Res Rev 5: 91–116.
49.
Staal, A., A.J. Van Wijnen, R.K. Desai, H.A. Pols, J.C. Birkenhager, H.F. Deluca, D.T. Denhardt, J.L. Stein, J.P. Van Leeuwen, G.S. Stein, J.B. Lian (1996) Antagonistic effects of transforming growth factor-β on vitamin D3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor/retinoid X receptor complexes with vitamin E response elements. Endocrinology 137: 2001–2011.
50.
Stepanovic, V., O. Awad, C. Jiao, M. Dunnwald, G.C. Schatteman (2003) Leprdb diabetic mouse bone marrow cells inhibit skin wound vascularization but promote wound healing. Circ Res 92: 1247–1253.
51.
Thornalley, P.J., A. Langborg, H.S. Minhas (1999) Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344: 109–116.
52.
Thorpe, S.R., J.W. Baynes (1996) Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 9: 69–77.
53.
Umeda, F., K. Inoue, K. Hirano, K. Mimura, J. Watanabe, M. Haji, K. Sueishi, H. Nawata (1992) Alterations in femoral bone histomorphometry and vitamin D metabolism in neonatal streptozotocin-induced diabetic rat. Fukuoka Igaku Zasshi 83: 403–408.
54.
Verzijl, N., R.A. Bank, J.M. TeKoppele, J. DeGroot (2003) AGEing and osteoarthritis: a different perspective. Curr Opin Rheumatol 15: 616–622.
55.
Vlassara, H. (1997) Recent progress in advanced glycation end products and diabetic complications. Diabetes 46(suppl 2): S19–S25.
56.
Wautier, M.P., P. Massin, P.J. Guillausseau, M. Huijberts, B. Levy, E. Boulanger, M. Laloi-Michelin, J.L. Wautier (2003) N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes Metab 29: 44–52.
57.
Yamagishi, S., K. Nakamura, H. Inoue (2005) Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients. Med Hypotheses 65: 1013–1015.
58.
Yamamoto, T., K. Ozono, A. Miyauchi, S. Kasayama, Y. Kojima, M. Shima, S. Okada (2001) Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. Am J Kidney Dis 38(4 suppl 1): S161–S164.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.